• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung.肺神经内分泌癌基因工程小鼠模型的比较病理学
J Thorac Oncol. 2015 Apr;10(4):553-64. doi: 10.1097/JTO.0000000000000459.
2
NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.NOTCH、ASCL1、p53和RB基因改变定义了一条驱动神经内分泌和小细胞肺癌的替代途径。
Int J Cancer. 2016 Feb 15;138(4):927-38. doi: 10.1002/ijc.29835. Epub 2015 Sep 25.
3
A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.一种前列腺素-大T抗原转基因小鼠品系会发展出具有转移潜能的前列腺腺癌和神经内分泌癌。
Cancer Res. 2001 Mar 1;61(5):2239-49.
4
Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features.定量逆转录-聚合酶链反应检测HASH1(ASCL1),一种具有神经内分泌特征的小细胞肺癌标志物。
Clin Cancer Res. 2002 Apr;8(4):1082-6.
5
Significance of achaete-scute complex homologue 1 (ASCL1) in pulmonary neuroendocrine carcinomas; RNA sequence analyses using small cell lung cancer cells and Ascl1-induced pulmonary neuroendocrine carcinoma cells.achaete-scute complex homologue 1 (ASCL1) 在肺神经内分泌癌中的意义;使用小细胞肺癌细胞和 Ascl1 诱导的肺神经内分泌癌细胞进行 RNA 序列分析。
Histochem Cell Biol. 2020 Jun;153(6):443-456. doi: 10.1007/s00418-020-01863-z. Epub 2020 Mar 13.
6
Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities.联合小细胞肺癌的综合分子分析确定了具有不同治疗机会的主要亚型。
ESMO Open. 2022 Feb;7(1):100308. doi: 10.1016/j.esmoop.2021.100308. Epub 2021 Dec 21.
7
Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors.神经内分泌性肺肿瘤谱系中视网膜母细胞瘤基因失活的机制
Am J Respir Cell Mol Biol. 1998 Feb;18(2):188-96. doi: 10.1165/ajrcmb.18.2.3008.
8
The significance of frequent and independent p53 and bcl-2 expression in large-cell neuroendocrine carcinomas of the lung.肺大细胞神经内分泌癌中频繁且独立的p53和bcl-2表达的意义。
Mod Pathol. 1999 Apr;12(4):362-9.
9
Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.肺神经内分泌肿瘤中p53、K-ras-2和C-raf-1的分析。与组织学亚型和临床结果的相关性。
Am J Pathol. 1996 May;148(5):1531-41.
10
Insights into the achaete-scute homolog-1 gene (hASH1) in normal and neoplastic human lung.正常和肿瘤人类肺组织中 Achaete-scute homolog-1 基因(hASH1)的研究进展。
Lung Cancer. 2012 Jan;75(1):58-65. doi: 10.1016/j.lungcan.2011.05.019.

引用本文的文献

1
Neuronal activity-dependent mechanisms of small cell lung cancer pathogenesis.小细胞肺癌发病机制中神经元活动依赖性机制
Nature. 2025 Sep 10. doi: 10.1038/s41586-025-09492-z.
2
Comparison of clinicopathologic features and prognosis between surgically resected pulmonary large-cell neuroendocrine carcinoma and small-cell lung cancer.手术切除的肺大细胞神经内分泌癌与小细胞肺癌的临床病理特征及预后比较
J Thorac Dis. 2025 Apr 30;17(4):2394-2410. doi: 10.21037/jtd-2025-345. Epub 2025 Apr 27.
3
Challenges of small cell lung cancer heterogeneity and phenotypic plasticity.小细胞肺癌异质性和表型可塑性的挑战。
Nat Rev Cancer. 2025 Apr 10. doi: 10.1038/s41568-025-00803-0.
4
Current and future therapies for small cell lung carcinoma.小细胞肺癌的当前及未来治疗方法
J Hematol Oncol. 2025 Apr 1;18(1):37. doi: 10.1186/s13045-025-01690-6.
5
Genomic Profiling of Extensive Stage Small-Cell Lung Cancer Patients Identifies Molecular Factors Associated with Survival.广泛期小细胞肺癌患者的基因组分析确定与生存相关的分子因素。
Lung Cancer (Auckl). 2025 Feb 20;16:11-23. doi: 10.2147/LCTT.S492825. eCollection 2025.
6
Characterization of A Bronchoscopically Induced Transgenic Lung Cancer Pig Model for Human Translatability.用于人类可转化性的支气管镜诱导转基因肺癌猪模型的特征描述
Res Sq. 2025 Feb 3:rs.3.rs-5054204. doi: 10.21203/rs.3.rs-5054204/v1.
7
Efficacy of cadonilimab and anlotinib combination in treating multiple drug‑resistant pulmonary large cell neuroendocrine carcinoma: A case report and literature review.卡度尼利单抗联合安罗替尼治疗多药耐药性肺大细胞神经内分泌癌的疗效:1例病例报告及文献复习
Oncol Lett. 2024 Oct 24;29(1):27. doi: 10.3892/ol.2024.14773. eCollection 2025 Jan.
8
Effect of Ki-67 proliferation index on survival in large cell neuroendocrine carcinoma of the lung.Ki-67 增殖指数对肺大细胞神经内分泌癌生存的影响。
Rev Assoc Med Bras (1992). 2024 Sep 16;70(9):e20240398. doi: 10.1590/1806-9282.20240398. eCollection 2024.
9
Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1.前列腺癌中的神经内分泌分化需要 ASCL1。
Cancer Res. 2024 Nov 4;84(21):3522-3537. doi: 10.1158/0008-5472.CAN-24-1388.
10
Nonviral CRISPR/Cas9 mutagenesis for streamlined generation of mouse lung cancer models.非病毒 CRISPR/Cas9 诱变技术用于简化小鼠肺癌模型的建立。
Proc Natl Acad Sci U S A. 2024 Jul 9;121(28):e2322917121. doi: 10.1073/pnas.2322917121. Epub 2024 Jul 3.

本文引用的文献

1
ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.ASCL1是一种谱系癌基因,为高级别神经内分泌肺癌提供治疗靶点。
Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14788-93. doi: 10.1073/pnas.1410419111. Epub 2014 Sep 29.
2
Mouse models of human cancer.人类癌症的小鼠模型。
Cancer Res. 2014 Sep 1;74(17):4671-5. doi: 10.1158/0008-5472.CAN-14-1424. Epub 2014 Aug 18.
3
Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing.通过基因组测序对小鼠小细胞肺癌进展进行遗传和克隆解析。
Cell. 2014 Mar 13;156(6):1298-1311. doi: 10.1016/j.cell.2014.02.031.
4
PTEN is a potent suppressor of small cell lung cancer.PTEN是小细胞肺癌的一种强效抑制因子。
Mol Cancer Res. 2014 May;12(5):654-9. doi: 10.1158/1541-7786.MCR-13-0554. Epub 2014 Jan 30.
5
Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells.利用重新衍生的胚胎干细胞快速验证复杂癌症小鼠模型中的靶基因。
EMBO Mol Med. 2014 Feb;6(2):212-25. doi: 10.1002/emmm.201303297. Epub 2014 Jan 8.
6
The pivotal role of IKKα in the development of spontaneous lung squamous cell carcinomas.IKKα 在自发性肺鳞癌发生发展中的关键作用。
Cancer Cell. 2013 Apr 15;23(4):527-40. doi: 10.1016/j.ccr.2013.03.009.
7
Mouse models for lung cancer.肺癌的小鼠模型。
Mol Oncol. 2013 Apr;7(2):165-77. doi: 10.1016/j.molonc.2013.02.010. Epub 2013 Feb 19.
8
Small-cell lung cancer: an update on targeted therapies.小细胞肺癌:靶向治疗的最新进展。
Adv Exp Med Biol. 2013;779:385-404. doi: 10.1007/978-1-4614-6176-0_18.
9
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer.全面的基因组分析确定 SOX2 是小细胞肺癌中经常扩增的基因。
Nat Genet. 2012 Oct;44(10):1111-6. doi: 10.1038/ng.2405. Epub 2012 Sep 2.
10
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.综合性基因组分析鉴定出小细胞肺癌的重要体细胞驱动突变。
Nat Genet. 2012 Oct;44(10):1104-10. doi: 10.1038/ng.2396. Epub 2012 Sep 2.

肺神经内分泌癌基因工程小鼠模型的比较病理学

The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung.

作者信息

Gazdar Adi F, Savage Trisha K, Johnson Jane E, Berns Anton, Sage Julien, Linnoila R Ilona, MacPherson David, McFadden David G, Farago Anna, Jacks Tyler, Travis William D, Brambilla Elisabeth

机构信息

*Hamon Center for Therapeutic Oncology Research and Department of Pathology, UT Southwestern Medical Center, Dallas, TX; †Department of Neuroscience, UT Southwestern Medical Center, Dallas, TX; ‡Cancer Genomics Centre, The Netherlands Cancer Institute, Amsterdam, The Netherlands; §Departments of Pediatrics and Genetics, Stanford University, Stanford, CA; ‖Center for Cancer Research, National Cancer Institute, Bethesda, MD; ¶Division of Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA; #David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02142; **Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY; and ††Departementd'Anatomie et Cytologie Pathologiques, INSERM Unit 823, Centre Hospitalier Universitaire Albert Michallon, and Institut Albert Bonniot University, Grenoble, France.

出版信息

J Thorac Oncol. 2015 Apr;10(4):553-64. doi: 10.1097/JTO.0000000000000459.

DOI:10.1097/JTO.0000000000000459
PMID:25675280
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4523224/
Abstract

INTRODUCTION

Because small-cell lung carcinomas (SCLC) are seldom resected, human materials for study are limited. Thus, genetically engineered mouse models (GEMMs) for SCLC and other high-grade lung neuroendocrine (NE) carcinomas are crucial for translational research.

METHODS

The pathologies of five GEMMs were studied in detail and consensus diagnoses reached by four lung cancer pathology experts. Hematoxylin and Eosin and immunostained slides of over 100 mice were obtained from the originating and other laboratories and digitalized. The GEMMs included the original Rb/p53 double knockout (Berns Laboratory) and triple knockouts from the Sage, MacPherson, and Jacks laboratories (double knockout model plus loss of p130 [Sage laboratory] or loss of Pten [MacPherson and Jacks laboratories]). In addition, a GEMM with constitutive co-expression of SV40 large T antigen and Ascl1 under the Scgb1a1 promoter from the Linnoila laboratory were included.

RESULTS

The lung tumors in all of the models had common as well as distinct pathological features. All three conditional knockout models resulted in multiple pulmonary tumors arising mainly from the central compartment (large bronchi) with foci of in situ carcinoma and NE cell hyperplasia. They consisted of inter- and intra-tumor mixtures of SCLC and large-cell NE cell carcinoma in varying proportions. Occasional adeno- or large-cell carcinomas were also seen. Extensive vascular and lymphatic invasion and metastases to the mediastinum and liver were noted, mainly of SCLC histology. In the Rb/p53/Pten triple knockout model from the MacPherson and Jacks laboratories and in the constitutive SV40/T antigen model many peripherally arising non-small-cell lung carcinoma tumors having varying degrees of NE marker expression were present (non-small-cell lung carcinoma-NE tumors). The resultant histological phenotypes were influenced by the introduction of specific genetic alterations, by inactivation of one or both alleles of specific genes, by time from Cre activation and by targeting of lung cells or NE cell subpopulations.

CONCLUSION

The five GEMM models studied are representative for the entire spectrum of human high-grade NE carcinomas and are also useful for the study of multistage pathogenesis and the metastatic properties of these tumors. They represent one of the most advanced forms of currently available GEMM models for the study of human cancer.

摘要

引言

由于小细胞肺癌(SCLC)很少进行手术切除,用于研究的人体材料有限。因此,用于SCLC和其他高级别肺神经内分泌(NE)癌的基因工程小鼠模型(GEMM)对于转化研究至关重要。

方法

详细研究了五种GEMM的病理情况,并由四位肺癌病理专家达成共识诊断。从原始实验室和其他实验室获取了100多只小鼠的苏木精和伊红染色以及免疫染色切片,并进行数字化处理。这些GEMM包括原始的Rb/p53双敲除模型(伯恩斯实验室)以及来自塞奇、麦克弗森和杰克斯实验室的三敲除模型(双敲除模型加上p130缺失[塞奇实验室]或Pten缺失[麦克弗森和杰克斯实验室])。此外,还包括来自利诺伊拉实验室的在Scgb1a1启动子控制下组成性共表达SV40大T抗原和Ascl1的GEMM。

结果

所有模型中的肺肿瘤都有共同的以及独特的病理特征。所有三个条件性敲除模型都导致多个肺肿瘤主要起源于中央区域(大气道),伴有原位癌灶和NE细胞增生。它们由不同比例的SCLC和大细胞NE细胞癌的肿瘤内和肿瘤间混合物组成。偶尔也可见腺癌或大细胞癌。注意到广泛的血管和淋巴管侵犯以及转移至纵隔和肝脏,主要为SCLC组织学类型。在麦克弗森和杰克斯实验室的Rb/p53/Pten三敲除模型以及组成性SV40/T抗原模型中,存在许多外周起源的具有不同程度NE标志物表达的非小细胞肺癌肿瘤(非小细胞肺癌-NE肿瘤)。所产生的组织学表型受特定基因改变的引入、特定基因一个或两个等位基因的失活、Cre激活后的时间以及肺细胞或NE细胞亚群的靶向作用影响。

结论

所研究的五个GEMM模型代表了人类高级别NE癌的整个谱系,也可用于研究这些肿瘤的多阶段发病机制和转移特性。它们代表了目前用于人类癌症研究的GEMM模型中最先进的形式之一。